Rhelion Life Sciences Corp.

As of June 30, 2026, Rhelion Life Sciences Corp. carries a market capitalization of 18.42M, placing it among publicly traded companies globally. Its enterprise value stands at 10.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rhelion Life Sciences Corp.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Rhelion Life Sciences Corp. has 614.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.40, and the price-to-book ratio stands at 0.98.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.97M versus a market cap of 18.42M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rhelion Life Sciences Corp. maintains a current ratio of 3.25, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.02, indicating elevated leverage, while an interest coverage ratio of -130.63 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Rhelion Life Sciences Corp. posted a negative return on equity (ROE) of -39.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.05, reflecting losses generated across the asset base. Inventory turnover of 2.53 indicates how many times Rhelion Life Sciences Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Rhelion Life Sciences Corp. recorded an income tax benefit of -304,673.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -7.60M and -6.94M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Rhelion Life Sciences Corp.'s stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.03.

Over the twelve months ended June 30, 2026, Rhelion Life Sciences Corp. generated 3.08M in revenue and converted that into -6.94M in net income, yielding earnings per share of -0.02. EBITDA reached -6.61M, while operating income came in at -4.38M.

As of June 30, 2026, Rhelion Life Sciences Corp. holds 8.13M in cash and equivalents against 1.45M in total debt, resulting in a net debt position of -1.44M. Total book value stands at 18.81M, with working capital of 7.68M providing operational flexibility.

Rhelion Life Sciences Corp. produced -2.91M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.09M in capital expenditures, free cash flow totaled -4.00M - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Rhelion Life Sciences Corp. posted a gross margin of 42.64, reflecting its pricing power and cost economics. The operating margin of -142.31 and net profit margin of -225.31 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -29.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Rhelion Life Sciences Corp. shareholders.

As of June 30, 2026, Rhelion Life Sciences Corp. has an Altman Z-Score of -2.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.